View or download posters and publications from 4D pharma plc

Archive:

Date 10 Nov 2022
Title SITC 2022 - Combination of MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation
Document (744KB)
Link —
Date 10 Nov 2022
Title SITC 2022 - Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy
Document (354KB)
Link —
Date 06 Jun 2022
Title Keystone Symposia: Neurodegeneration - Harnessing the Neuromodulatory Effects of Live Biotherapeutic Products (LBPs) Derived from the Gut Microbiota to Treat Parkinson’s Disease
Document (819KB)
Link —
Date 03 Jun 2022
Title ASCO 2022 - Trial in progress: A Phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing ch
Document (318KB)
Link —
Date 17 May 2022
Title ATS 2022 - Safety, Tolerability and Preliminary Signals of Activity in Adult Patients with Partly Controlled Asthma Treated with Live Biotherapeutic MRx-4DP0004 as an Add-On Maintenance Therapy to Inhaled Corticosteroids (ICS) With or Without Long-Acting
Document (275KB)
Link —
Date 09 Dec 2021
Title Gastro 2021 - Administration of a Live Biotherapeutic is associated with Microbiome Structural Changes and the Alleviation of IBS symptomology: Results from Blautix® Phase II RCT
Document (2,067KB)
Link —
Date 16 Sep 2021
Title ESMO 2021 - Baseline biomarkers associated with clinical benefit in patients with solid tumours refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab
Document (1,024KB)
Link —
Date 16 Sep 2021
Title ESMO 2021 - Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours
Document (495KB)
Link —
Date 06 Jul 2021
Title Publication - Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer, Nature Communications
Document —
Link visit
Date 25 May 2021
Title DDW 2021 Virtual R&D Event: Phase II clinical trial of Blautix as a treatment for IBS-C and IBS-D
Document (428KB)
Link —
Date 24 May 2021
Title DDW 2021 - A Phase II randomized, multi-center study to evaluate the efficacy and safety of the oral single strain Live Biotherapeutic Product (LBP) Blautix in subjects with IBS-C and IBS-D
Document (288KB)
Link —
Date 04 May 2021
Title Keystone Symposia, Synthetic Biology: At the Crossroads of Genetic Engineering and Human Therapeutics. Engineering live biotherapeutics: approaches, challenges and applications
Document (859KB)
Link —
Date 08 Jan 2021
Title Publication - The fecal mycobiome in patients with Irritable Bowel Syndrome, Scientific Reports
Document —
Link visit
Date 09 Nov 2020
Title SITC2020, 4D presents first monotherapy data for immuno-oncology LBP MRx0518 in neoadjuvant setting, demonstrating tumor and systemic immune modulation
Document (842KB)
Link —
Date 09 Nov 2020
Title SITC2020, 4D presents updated clinical benefit results from Part A of its trial of MRx0518 in combination with pembrolizumab in refractory solid tumors
Document (488KB)
Link —
Date 09 Nov 2020
Title SITC2020, trial-in-progress (TiP) poster describing ongoing Part B of its Phase I/II trial of MRx0518 in combination with pembrolizumab in refractory solid tumors
Document (461KB)
Link —
Date 07 Jun 2020
Title 4D presents preclinical LBP candidates for neurodegenerative disease and autism at Microbiome Connect Human USA
Document (2,781KB)
Link —
Date 29 Apr 2020
Title 4D and OncoDesign present joint AACR poster with additional analysis of MRx0518 activity in pre-clinical model of breast cancer
Document (647KB)
Link —
Date 21 Mar 2020
Title Publication - Quality by Design: comparison of design space construction methods in the case of Design of Experiments
Document —
Link visit
Date 16 Dec 2019
Title Publication - Differences in the microbiome and metabolome of people with irritable bowel syndrome and bile acid malabsorption
Document —
Link visit
Date 06 Dec 2019
Title 4D presents at the Microbiome Movement Gut-Brain-Axis Summit in Boston
Document (2,651KB)
Link —
Date 06 Dec 2019
Title 4D presents on the immunology of MRx-4DP0004 in vitro and in a model of severe asthma, at the British Society of Immunology Congress 2019
Document (835KB)
Link —
Date 06 Dec 2019
Title 4D presents the preclinical anti-tumour activity and immunology of immuno-oncology LBP MRx0518 at the British Society for Immunology 2019
Document (704KB)
Link —
Date 14 Nov 2019
Title 4D presents at the European Microbiome Congress, on LBPs targeting the gut-brain axis
Document (2,410KB)
Link —
Date 11 Nov 2019
Title 4D present trial-in-progress poster at SITC 2019, detailing Phase I study of neoadjuvant MRx0518 before surgical resection of solid tumours
Document (587KB)
Link —
Date 24 Oct 2019
Title 4D presents pre-clinical data on two candidates for neurodegenerative disease at Neuroscience 2019
Document (789KB)
Link —
Date 10 Oct 2019
Title 4D pharma presents on bacterial SCFA metabolites as HDAC inhibitors
Document (783KB)
Link —
Date 10 Oct 2019
Title 4D pharma presents pre-clinical data on two LBP candidates for neurodegenerative disease
Document (673KB)
Link —
Date 10 Oct 2019
Title 4D pharma presents additional analysis of Blautix Phase Ib study in IBS
Document (772KB)
Link —
Date 20 Sep 2019
Title Publication - In vitro Characterization of Gut Microbiota-Derived Bacterial Strains With Neuroprotective Properties
Document —
Link visit
Date 09 Sep 2019
Title Publication - Identification performance of MALDI-ToF-MS upon mono- and bi-microbial cultures is cell number and culture proportion dependent
Document —
Link visit
Date 25 Jul 2019
Title 4D pharma presents new mechanistic data for oncology programmes
Document (3,248KB)
Link —
Date 25 Jul 2019
Title 4D pharma presentation at Oncology Response Summit 2019. Into the Clinic: Challenges & Opportunities
Document (1,294KB)
Link —
Date 20 Jun 2019
Title 4D pharma presents at Keystone Symposia:Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, USA
Document (1,475KB)
Link —
Date 07 Jun 2019
Title 4D Presents Phase Ib Clinical Data on Thetanix® at ESPGHAN
Document (1,511KB)
Link —
Date 03 Jun 2019
Title 4D presents MRx0518 combination study at ASCO 2019, Chicago, USA
Document (581KB)
Link —
Date 21 May 2019
Title 4D presents on lead immuno-oncology candidate MRx0518 at 4th Annual Advances in Immuno-Oncology Congress, London, UK
Document (3,895KB)
Link —
Date 19 May 2019
Title 4D Presents Phase Ib Clinical Data on Thetanix® at Digestive Disease Week, San Diego
Document (664KB)
Link —
Date 13 May 2019
Title 4D announces participation in Neuro4D Conference, Frankfurt, Germany
Document (629KB)
Link —
Date 08 Mar 2019
Title 4D announces participation in Chardan’s Inaugural Microbiome Medicines Summit, USA
Document —
Link visit
Date 30 Jan 2019
Title 4D pharma presents on MRx0518 at Microbiome Movement - Drug Development Europe, Paris
Document (2,424KB)
Link —
Date 29 Jan 2019
Title 4D pharma announces publication of data highlighting immuno-stimulatory properties of MRx0518
Document —
Link visit
Date 28 Nov 2018
Title Chardan Microbiome Medicines Landscape Webinar
Document —
Link visit
Date 29 Oct 2018
Title 4D pharma present on efficacy of asthma candidate MRx-4DP0004 in a model of severe asthma, Microbiome R&D and Business Collaboration Forum, San Diego, USA
Document (1,058KB)
Link —
Date 11 Oct 2018
Title 4D Key Opinion Leader Luncheon: Immuno-oncology
Document (4,087KB)
Link visit
Date 02 Oct 2018
Title 4D present on discovery and development of microbiome-based therapeutics in asthma and immuno-oncology, Microbiome Summit, Vienna, Austria
Document (1,676KB)
Link —
Date 16 Sep 2018
Title 4D present on mechanisms of asthma programme MRx0004, EMBO/EMBL Symposia: The Human Microbiome, Heidelberg, Germany
Document (860KB)
Link —
Date 14 Aug 2018
Title 4D asthma publication
Document —
Link visit
Date 30 Jul 2018
Title Publication - microbiota as HDAC inhibitors
Document —
Link visit
Date 27 Jun 2018
Title 4D presents, Live Biotherapeutics: Form Follows Functions, at IHMC 2018
Document (1,593KB)
Link visit
Date 26 Jun 2018
Title 4D present data on IBS microbiome analysis at IHMC Conference, Killarney, Ireland
Document (866KB)
Link —
Date 26 Jun 2018
Title 4D present data on gut bacterial strains able to modulate neuroinflammation and neurodegeneration, IHMC Conference, Killarney, Ireland
Document (525KB)
Link —
Date 04 Jun 2018
Title 4D Presents Phase Ib Clinical Data on Blautix
Document (457KB)
Link visit
Date 04 Jun 2018
Title Live Biotherapeutics - From Concept to Clinic in Immuno-Oncology
Document (1,987KB)
Link —
Date 21 Mar 2018
Title 4D presents data on MRx0518 MoA in immuno-oncology
Document (1,215KB)
Link —
Date 12 Feb 2018
Title Live biotherapeutics and immuno-oncology: from discovery to efficacy studies, Cell-Weizmann Institute of Science Symposium: Next Gen Immunology Congress, Rehovot, Isreal
Document (927KB)
Link —
Date 05 Feb 2017
Title 4D pharma presents data on asthma programme
Document (643KB)
Link —
Date 05 Feb 2017
Title 4D pharma presents data on RA programme
Document (1,452KB)
Link —

BACK TO TOP